US FDA advisors say 'no' to Sanofi's semuloparin for VTE prevention in cancer patients
This article was originally published in Scrip
Executive Summary
Hopes for approval by the US FDA of a new blood thinning drug developed by Sanofi-Aventis dimmed considerably 20 June, when the agency's Oncologic Drug Advisory Committee (ODAC) of outside experts took an unequivocal stance against approving the product.